This is a preview of subscription content, log in via an institution to check access.
References
Birkmayer, W., Hornykiewicz, O. Der L-3, 4-Dioxyphenylalanin(=Dopa)-Effekt beim Parkinson-Syndrom des Menschen. Arch. Psychiat. Nervenkr.203, 560–574 (1962).
Birkmayer, W., Hornykiewicz, O. Advances in Parkinsonism, pp. 381–396. Basle: Editiones Roche. 1976.
Birkmayer, W., Neumayer, E. Die moderne medikamentöse Behandlung des Parkinsonismus. Z. Neurol.202, 257 (1972).
Birkmayer, W., Riederer, P., Youdim, M. B. H., Linauer, W. The potentiation of the anti-akinetic effect after L-DOPA treatment by an inhibitor of MAO-B, deprenyl. J. Neural Transm.36, 303–326 (1975).
Birkmayer, W., Riederer, P., Ambrozi, L., Youdim, M. B. H. Implications of Combined Treatment with Madopar and L-Deprenyl in Parkinson's disease. Lancetii, 439–443 (1977).
Johnston, J. P. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol.17, 1285 (1968).
Knoll, J., Vizi, E. S., Somogyi, G. Phenylisopropylmethylpropinylamine (E-250), a monoamine oxidase inhibitor antagonizing the effects of tyramine. Arzneim.-Forsch.18, 109 (1968).
Lees, A. J., Shaw, K. M., Kohout, L. J., Stern, G. M., Elsworth, J. D., Sandler, M., Youdim, M. B. H. Deprenyl in Parkinson's disease. Lancetii, 791–796 (1977).
Youdim, M. B. H., Collins, G., Sandler, M., Bevan Jones, A. B., Pare, C. M. B., Nicholson, W. J. Human Brain Monoamine Oxidase, Multiple Forms and Selective Inhibitors. Nature (London)236, 225–228 (1972).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Birkmayer, W. Long term treatment with L-deprenyl. J. Neural Transmission 43, 239–244 (1978). https://doi.org/10.1007/BF01246960
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01246960